Trial Profile
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2023
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine (Primary) ; ADVAX; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms HBV003
- Sponsors Vaxine
- 28 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 28 Mar 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 28 Mar 2023 Planned initiation date changed from 1 Sep 2022 to 1 Sep 2023.